Yajie Zhang

Dr. Yajie Zhang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YXYawei Xu
Yawei Xu
YZYajie Zhang
Yajie Zhang
YHYunfei Huang
Yunfei Huang
LLLu Li
Lu Li
MSMengna Shi
Mengna Shi
CLChunmei Li
Chunmei Li
Epidemiological and clinical evidence indicates that obesity-associated metabolic dysfunction increases the risk of depression, which is often resistant to conventional antidepressant therapies. Elucidating targeted mechanisms underlying obesity-related depression is therefore essential for developing effective interventions. Accumulating evidence identifies neuroinflammation as a central link between obesity and depressive disorders. Obesity-driven inflammatory signaling disrupts multiple neurobiological processes implicated in depression, thereby contributing to the onset and progression of inflammatory depression. Polyphenols, a diverse class of plant-derived secondary metabolites, have demonstrated neuroprotective properties, attributed to their anti-inflammatory, antioxidant, and metabolic regulatory effects. By restoring neurobiological homeostasis, polyphenols may represent a promising therapeutic strategy for obesity-related inflammatory depression. This review summarizes the pathophysiological mechanisms through which obesity induces neuroinflammation and subsequently promotes depressive symptoms. It further evaluates current evidence regarding the efficacy and effective dosing of polyphenols in attenuating inflammatory signaling and alleviating obesity-related inflammatory depression, as well as the translational challenges faced in their clinical application. Given their anti-neuroinflammatory potential, polyphenols may serve as a valuable adjunctive approach for the management of obesity-related inflammatory depression.

15 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
YXYawei Xu
Yawei Xu
YZYajie Zhang
Yajie Zhang
YHYunfei Huang
Yunfei Huang
LLLu Li
Lu Li
MSMengna Shi
Mengna Shi
CLChunmei Li
Chunmei Li
Epidemiological and clinical evidence indicates that obesity-associated metabolic dysfunction increases the risk of depression, which is often resistant to conventional antidepressant therapies. Elucidating targeted mechanisms underlying obesity-induced depression is therefore essential for developing effective interventions. Accumulating evidence identifies neuroinflammation as a central link between obesity and depressive disorders. Obesity-driven inflammatory signaling disrupts multiple neurobiological processes implicated in depression, thereby contributing to the onset and progression of inflammatory depression. Polyphenols, a diverse class of plant-derived secondary metabolites, have demonstrated neuroprotective properties, largely attributed to their anti-neuroinflammatory effects. By modulating inflammatory pathways and restoring neurobiological homeostasis, polyphenols may represent a promising therapeutic strategy for obesity-related depression. This review summarizes the pathophysiological mechanisms through which obesity induces neuroinflammation and subsequently promotes depressive symptoms. It further evaluates current evidence regarding the efficacy and effective dosing of polyphenols in attenuating inflammatory signaling and alleviating obesity-associated inflammatory depression. Given their anti-neuroinflammatory potential, polyphenols may serve as a valuable adjunctive approach for the management of obesity-induced depression.

18 May 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
YZYajie Zhang
Yajie Zhang
YHYunfei Huang
Yunfei Huang
YXYawei Xu
Yawei Xu
CLChunmei Li
Chunmei Li
Background/Objectives: Obesity represents a significant global health challenge. Although alternate-day fasting (ADF) has been shown to effectively improve metabolic parameters, long-term adherence to this regimen remains limited. This study aimed to investigate whether highly polymerized persimmon tannin (DP31) could serve as a practical alternative to ADF for the prevention of high-fat diet (HFD)-induced obesity in mice. Methods: Male C57BL/6J mice (n = 10 per group) were subjected to an HFD for 11 weeks, during which they concurrently received either DP31 or ADF. Body weight, fat mass, serum lipid levels, glucose tolerance, fasting glucose, and insulin levels were assessed. Additionally, hepatic transcriptomics, Western blotting, 16S rRNA sequencing, and short-chain fatty acids (SCFAs) analysis were conducted. Results: DP31 demonstrated comparable efficacy to ADF in reducing body weight gain and improving lipid profiles, while exhibiting superior effects on glucose tolerance and fasting glucose levels (p < 0.05). Both interventions effectively reversed HFD-induced hepatic gene dysregulation, leading to the upregulation of genes involved in processes related to steroid metabolism. In addition, both treatments activated the hepatic AMPK-mTORC1-Lpin1 axis, suppressed lipogenesis, upregulated PGC1α, and increased β-hydroxybutyrate levels, indicating enhanced fatty acid oxidation (p < 0.05). Notably, DP31 outperformed ADF in enriching beneficial gut genera, such as Akkermansia, and boosting SCFAs production, which may elucidate its superior glycemic control. Overall, DP31 exhibits comparable effects to ADF in preventing obesity-related metabolic disorders, while demonstrating superior effects on glucose homeostasis.